ArticleESMO gastrointestinal oncology2026
Health-related quality of life in biliary tract cancer clinical trials. The current state and future directions.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with biliary tract cancers (BTCs) often experience a decline in health-related quality of life (HRQoL). Patient-reported outcome measures (PROMs), usually collected through HRQoL questionnaires, offer a standardized approach to capturing the patient's perspective. This study aimed to provide a comprehensive analysis of HRQoL in BTC clinical trials. Design: After database screening, the 30 most impactful clinical trials in BTC were identified for evaluation of HRQoL reporting and analysis. The primary objective was to determine the proportion of trials that included HRQoL assessment. Secondary objectives were to examine different aspects of HRQoL analysis and to assess the robustness of reporting using the recently developed European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) HRQoL checklist. Results: Fifteen trials (50%) included HRQoL in their design, with published results available for 14. The most frequent HRQoL outcome was stability (i.e. neither improvement nor deterioration). The median ESMO-MCBS HRQoL checklist score was 11 (interquartile range 9.00-11.75). Conclusions: HRQoL remains only partially addressed in BTC clinical trials. Tools such as the ESMO HRQoL checklist and electronic PROMs may strengthen the assessment and highlight the importance of HRQoL in both clinical trials and routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.